凝血酶原片段F1+2(F1+2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Prothrombin Fragment 1+2 (F1+2)
- 編號(hào)SEA710Hu
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍3.9-250pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于1.5pg/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 2646¥ 3780¥ 17010¥ 32130¥ 264600
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)凝血酶原片段F1+2(F1+2)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的凝血酶原片段F1+2(F1+2)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 78-99 | 93 |
| EDTA plasma(n=5) | 96-105 | 101 |
| heparin plasma(n=5) | 97-104 | 101 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的凝血酶原片段F1+2(F1+2)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中凝血酶原片段F1+2(F1+2)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 90-99% | 78-103% | 85-102% | 98-105% |
| EDTA plasma(n=5) | 88-101% | 83-104% | 84-98% | 84-101% |
| heparin plasma(n=5) | 80-99% | 84-99% | 84-101% | 88-102% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將F1抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的F1與連接于固相載體上的抗體結(jié)合，然后加入生物素化的F2抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的F1+2呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA710Hu01 | 凝血酶原片段F1+2(F1+2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA710Hu01 | 凝血酶原片段F1+2(F1+2)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA710Hu71 | 凝血酶原片段F1+2(F1+2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAA710Hu22 | 凝血酶原片段F1+2(F1+2)單克隆抗體 | WB; IHC |
| MAA710Hu23 | 凝血酶原片段F1+2(F1+2)單克隆抗體 | WB; IHC; ICC/IF |
| MAA710Hu24 | 凝血酶原片段F1+2(F1+2)單克隆抗體 | WB; IHC |
| MAA710Hu25 | 凝血酶原片段F1+2(F1+2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA710Hu21 | 凝血酶原片段F1+2(F1+2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA710Hu26 | 凝血酶原片段F1+2(F1+2)單克隆抗體 | WB; IHC; ICC; IP. |
| FAA710Hu02 | 抗凝血酶原片段F1+2(F1+2)單克隆抗體 | Flow cytometry. |
| LAA710Hu72 | 凝血酶原片段F1+2(F1+2)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEA710Hu | 凝血酶原片段F1+2(F1+2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| HEA710Hu | 凝血酶原片段F1+2(F1+2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA710Hu | 凝血酶原片段F1+2(F1+2)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA710Hu | 凝血酶原片段F1+2(F1+2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| PSA710Hu01 | 凝血酶原片段F1+2(F1+2)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| KSA710Hu01 | 凝血酶原片段F1+2(F1+2)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | 自己動(dòng)手制作ELISA試劑盒的主要材料 |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Critical Care | Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study[BioMed: cc10553] |
| Journal of Vascular Surgery | Changes in thrombin generation, fibrinolysis, platelet and endothelial cell activity, and inflammation following endovascular abdominal aortic aneurysm repair[ScienceDirect: S0741521411018568] |
| Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine | High levels of soluble VEGF receptor 1 early after trauma are associated with shock, sympathoadrenal activation, glycocalyx degradation and inflammation in severely injured patients: a prospective study[Sjtrem:1757-7241] |
| Journal of Thrombosis and Haemostasis | High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality[Wiley: source] |
| British Journal of Dermatology | Evaluation of autologous plasma skin test in patients with chronic idiopathic urticaria[PubMed: 21910697] |
| Arteriosclerosis, Thrombosis, and Vascular Biology. | Diet Modulates Endogenous Thrombin Generation, A Biological Estimate of Thrombosis Risk, Independently of the Metabolic Status[PubMed: 22859493] |
| Journal of Vascular Surgery | Medium-term effect of endovascular and open abdominal aortic aneurysm repair on thrombin generation and fibrinolysis[PubMed: 23140799] |
| PLoS ONE | Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension[Plosone: Source] |
| Journal of Vascular Surgery | Effect of endovascular and open abdominal aortic aneurysm repair on thrombin generation and fibrinolysis[Pubmed: 23140799 ] |
| Haemetology | Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India[Pubmed: 23992124] |
| Cogent Medicine | Study the association of adiponectin with inflammation and hypercoagulability in case of type 2 diabetic subjects with renal dysfunction[Tandfonline:Source] |
| Interact Cardiovasc Thorac Surg. | An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose[Pubmed:24632424] |
| Perfusion | Ex vivo simulation of cardiopulmonary bypass with human blood for hemocompatibility testing[PubMed: 26243277] |
| J Thromb Haemost | Comparison of the Effect of Dabigatran and Dalteparin on Thrombus Stability in a Murine Model of Venous Thromboembolism[PubMed: 26514101] |
| Acta Oncologica Turcica | Thrombin activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI), and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer [aot:AOT_49_1_6_12.pdf] |
| Advances in Medical Sciences | Perioperative thrombocytopenia predicts poor outcome in patients undergoing transcatheter aortic valve implantation[pubmed:29145170] |
| Thrombosis Research | The causes of thrombocytopenia after transcatheter aortic valve implantation[pubmed:28582640] |
| Acta?Haematologica | Elevations of Thrombotic Biomarkers in Hemoglobin H Disease[Pubmed:29402840] |
| Journal of Neurotrauma | The cerebral thrombin system is activated after intracerebral hemorrhage and contributes to secondary lesion growth and poor neurological outcome in C57Bl/6 mice[Pubmed: 31830857] |
| Indian Journal of Public Health Research & Development | Enhanced Fibrin-Lysis in Grade-1 Dengue Haemorrhagic Fever[] |
| Rheumatol Int | The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary?…[Pubmed:35284968] |
